Thrombosis Update最新文献

{"title":"Magnitude of hemorrhagic complications and its associated factors among patients on anticoagulant therapy at University of Gondar Comprehensive and Specialized Hospital, Northwest Ethiopia","authors":"Eden Abetu Mehari ,&nbsp;Abebe Basazn Mekuria ,&nbsp;Mestayet Geta ,&nbsp;Eshetie Melese Birru","doi":"10.1016/j.tru.2023.100130","DOIUrl":"10.1016/j.tru.2023.100130","url":null,"abstract":"<div><h3>Background</h3><p>Despite the well-established effectiveness of anticoagulants, the risk of their hemorrhagic complications withheld many patients from being maintained on anticoagulant therapy. However, there is no sufficient data on the magnitude and factors associated with anticoagulant-related hemorrhagic complications in resource-constrained settings. Thus this study aimed to assess the magnitude of hemorrhagic complications and associated factors related to anticoagulant therapy among patients at the University Of Gondar Comprehensive and Specialized Hospital.</p></div><div><h3>Methods</h3><p>A retrospective follow-up study was done on 154 individuals starting from June 2018 to June 2019 on adult patients who had completed their anticoagulant therapy at the University of Gondar specialized and comprehensive hospital. They were selected using a systematic random sampling technique among all patients who had completed their anticoagulant therapy which is heparin, warfarin, or both. A retrospective data after the initiation of anticoagulant therapy was collected. The data collection was conducted from July 1 to August 30, 2019. Bivariable and multivariable logistic regression was used to identify factors. Variables with p &lt; 0.05 were considered statistically significant.</p></div><div><h3>Results</h3><p>Out of 154 patients who received anticoagulant therapy during the study period, more than half 83 (53.9%) of the participants were female, and the mean age of participants was 54.8 ± 21.1 years. A quarter of patients, 38 (24.7%), 95% CI (17.8, 31.6) who had been on anticoagulant therapy experienced bleeding complications. Being female (AOR = 6.12, 95% CI: 1.81, 20.71, <em>P</em> = 0.004) Aspirin use (AOR = 7.71, 95% CI: 2.24, 26.53, <em>P</em> = 0.001), type of anticoagulant (AOR = 4.94, 95% CI: 1.58, 15.49, <em>P</em> = 0.006), and number of co-morbidities(AOR = 4.99, 95% CI: 1.47, 16.95, <em>P</em> = 0.010) were found to be significantly associated with hemorrhagic complications.</p></div><div><h3>Conclusions</h3><p>Hemorrhagic complications related to anticoagulant therapy are not rare. Therefore close monitoring of coagulation profiles as well as minimization of risk factors is crucial and needs collaborated work of all health care professionals and decision-makers.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"10 ","pages":"Article 100130"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48895790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute limb ischemia in COVID-19 patients despite therapeutic anticoagulation: Experience from Africa","authors":"Fikremariam Melkeneh Alemayehu ,&nbsp;Dawit Kebede Huluka ,&nbsp;Tizazu Kebede Beyene ,&nbsp;Azmera Gissila Aboye ,&nbsp;Hiwotie Abebe Mesfin","doi":"10.1016/j.tru.2022.100128","DOIUrl":"10.1016/j.tru.2022.100128","url":null,"abstract":"<div><h3>Background</h3><p>Hypercoagulability is a common complication seen in COVID-19 infection. However, arterial thrombosis such as acute limb ischemia (ALI) is far less common. Data on the incidence and nature of arterial thromboembolic complications in patients with COVID-19 is limited, originating from a few case reports and case series. Data in the African continent are very scarce.</p></div><div><h3>Method</h3><p>This is a case series of 10 patients with COVID-19 who developed ALI while on treatment at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. All patients with ALI and COVID-19 admitted between February 1, 2021, and December 31, 2021, were retrospectively identified and reviewed. COVID-19 was confirmed by RT-PCR and ALI was confirmed by Doppler ultrasound and/or computed tomography angiography in the presence of clinical suspicion.</p></div><div><h3>Results</h3><p>A total of 3098 patients were hospitalized with confirmed COVID-19 during the study period. In a series of 10 patients, 8 (80%) males with a median age of 53.5 years were included. All except one (10%) had one or more risk factors for ALI and one had a ‘possible’ case of vaccine-induced thrombotic thrombocytopenia (VITT) associated with ALI. All were admitted with severe COVID-19 and most (80%) developed ALI during hospitalization (median of seven days from admission). The median duration between COVID-19 and ALI symptom onset was 14.5 days (IQR, 11–15). The majority (60%) were taking therapeutic anticoagulation at the time of ALI onset which is the standard of care for patients with severe disease. Five (50%) were successfully revascularized (median time of 3.5 days) and the rest underwent amputation. All survived and were discharged improved.</p></div><div><h3>Conclusion</h3><p>ALI can occur in the context of COVID-19 even while a patient is on therapeutic dose anticoagulation and in the absence of traditional risk factors. It is wise to be vigilant of this complication for timely intervention and better treatment outcomes.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"10 ","pages":"Article 100128"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42585473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"VTE epidemiology and challenges for VTE prevention at the population level","authors":"Sigrid K. Brækkan ,&nbsp;John-Bjarne Hansen","doi":"10.1016/j.tru.2023.100132","DOIUrl":"10.1016/j.tru.2023.100132","url":null,"abstract":"<div><p>Venous thromboembolism (VTE) is a frequent disease affecting more than 1 in 12 individuals during their lifetime. VTE is associated with a substantial disease burden due to long-term complications such as recurrence, the post-thrombotic syndrome, and the post-pulmonary embolism syndrome. Despite the knowledge of several risk factors and triggers, more than one third of the VTE events occur in the absence of an obvious provoking factor. In this narrative review, we summarize studies presenting time trends in incidence rates of VTE after year 2000 and discuss potential reasons for the incidence trends as well as challenges for VTE prevention at the population level. Studies from US, Europe and Asia indicate that the incidence rates of VTE have increased slightly during the last twenty years. Of note, this increase has persisted beyond the implementation of computed tomography pulmonary angiography (CTPA) into routine clinical practice. The persisting rates are likely attributed to the concomitant increase in major risk factors for VTE, such as obesity, major surgery, and cancer. Apparently, more widespread use of thromboprophylaxis to high-risk groups have not counteracted the rates noticeably, indicating that an approach to change the risk factor profile in the general population may be warranted. Obesity is recognized as the strongest causal lifestyle factor for VTE with a population attributable fraction of 10–30%. However, the mechanisms by which obesity increases the VTE risk are poorly understood. By integrating multi-omics and system biology approaches, future epidemiological studies should focus on identifying biological pathways that drive thrombogenesis to reveal disease mechanisms and potential targets for prevention.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"10 ","pages":"Article 100132"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46427604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19","authors":"Faria Khimani ,&nbsp;Adam J. Wolf ,&nbsp;Braian Yoon ,&nbsp;Amy Blancke ,&nbsp;Coltin Gerhart ,&nbsp;Dakota Endsley ,&nbsp;Alleyna Dougherty ,&nbsp;Anish K. Ray ,&nbsp;Angelito F. Yango ,&nbsp;Stuart D. Flynn ,&nbsp;Gregory Y.H. Lip ,&nbsp;Stevan A. Gonzalez ,&nbsp;Mohanakrishnan Sathyamoorthy","doi":"10.1016/j.tru.2022.100126","DOIUrl":"10.1016/j.tru.2022.100126","url":null,"abstract":"<div><p>Thrombosis is a known complication of SARS-CoV-2 infection, particularly within a severely symptomatic subset of patients with COVID-19 disease, in whom an aggressive host immune response leads to cytokine storm syndrome (CSS). The incidence of thrombotic events coinciding with CSS may contribute to the severe morbidity and mortality observed in association with COVID-19. This review provides an overview of pharmacologic approaches based upon an emerging understanding of the mechanisms responsible for thrombosis across a spectrum of COVID-19 disease involving an interplay between immunologic and pro-thrombotic events, including endothelial injury, platelet activation, altered coagulation pathways, and impaired fibrinolysis.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"10 ","pages":"Article 100126"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43726524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bleeding and venous thromboembolism events in cancer patients taking direct oral anticoagulants vs. low molecular weight heparin","authors":"Frank A. Lattuca,&nbsp;Jeremiah Moore,&nbsp;Carissa Treptow,&nbsp;Kendra Delibert,&nbsp;Andrea Baran,&nbsp;Frank Akwaa","doi":"10.1016/j.tru.2022.100129","DOIUrl":"10.1016/j.tru.2022.100129","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients with cancer have an increased risk of developing venous thromboembolism (VTE), and subsequently a higher risk of bleeding secondary to anticoagulants. Low-molecular weight heparin (LMWH) has been the standard of care for these patients, with emerging data on the use of direct oral anticoagulants (DOACs). The primary objective of the study was to determine the prevalence of major bleeding events in cancer patients taking DOACs or LMWH for VTE. Secondary objectives included the rate of first VTE recurrence and the effect of concomitant antiplatelet agents and/or significant drug interactions on major bleeding or recurrent VTE.</p></div><div><h3>Materials and methods</h3><p>Using the electronic medical record at the University of Rochester Medical Center, we retrospectively identified adult patients with active malignancy who had a diagnosis of VTE requiring therapeutic anticoagulation within the study period of July 1st, 2015 to June 1st, 2019. Patients were excluded if they were receiving prophylactic doses of LMWH per the institution VTE guidelines. Data on anticoagulant medications were collected as well as information on major bleeding and recurrent VTE events.</p></div><div><h3>Results and conclusions</h3><p>There is insufficient evidence of difference in risk of major bleeding among patients who received a DOAC vs LMWH (cause-specific hazard ratio (HR) = 0.77, 95% CI 0.29–2.04, P = 0.60). There was also no evidence of a difference in risk of recurrent VTE between patients who received DOAC vs. LMWH (cause-specific HR = 0.98, 95% CI 0.15–6.26, P = 0.98). These results suggest that DOACs are not significantly less safe than LMWH for patients with cancer.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"10 ","pages":"Article 100129"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46046028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing anticoagulation stewardship: A call to action for stewardship from the US-based anticoagulation forum","authors":"Allison Burnett ,&nbsp;Kelly M. Rudd ,&nbsp;Darren Triller","doi":"10.1016/j.tru.2022.100125","DOIUrl":"10.1016/j.tru.2022.100125","url":null,"abstract":"<div><h3>Purpose</h3><p>Anticoagulation Stewardship is urgently needed to improve anticoagulation management and bend the current, negative trajectory on anticoagulation-related harm. This manuscript catalogs the origins and the progression of the Anticoagulation Stewardship model and serves as a call to action for healthcare providers and organizations committed to improving the quality and safety of anticoagulation management.</p></div><div><h3>Key elements</h3><p>Tens of millions of patients around the world currently require anticoagulant therapy to prevent or treat thrombotic events. Concerningly, there is a growing body of evidence confirming that increasing volume and complexity of anticoagulant use is significantly impacting the therapeutic landscape, posing major challenges to safe prescribing and management of these high-risk, yet essential therapies, and leading to increased patient harm including life-threatening bleeding and thrombotic complications across the continuum of care. In response, anticoagulation stewardship programs, modeled after highly successful antimicrobial stewardship efforts, are gaining increased traction to counteract this growing health concern.</p></div><div><h3>Conclusions</h3><p>The current health care system is inadequate to protect patients from avoidable harms and to maximize the benefits of therapy. Apart from anticoagulation stewardship, there does not currently exist another cross-setting, multidisciplinary model for achieving maximum quality and safety for patients. If we are to collectively meet the challenge that stands before us, we must commit ourselves (as individuals and organizations) to leveraging the available resources to advance the anticoagulation stewardship model while also contributing to the burden of evidence and the effective articulation of the stewardship message.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100125"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000293/pdfft?md5=3174b515a737686e708c352eecfb63dc&pid=1-s2.0-S2666572722000293-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43156452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ADAMTS13 levels in a plasma-derived FVIII concentrate: A potential therapeutic option for patients with congenital thrombotic thrombocytopenic purpura","authors":"Filippo Mori ,&nbsp;Ilaria Nardini ,&nbsp;Silvia Nannizzi ,&nbsp;Roberto Crea ,&nbsp;Prasad Mathew ,&nbsp;Nicole Ziliotto ,&nbsp;Alessandro Gringeri","doi":"10.1016/j.tru.2022.100120","DOIUrl":"10.1016/j.tru.2022.100120","url":null,"abstract":"<div><h3>Introduction</h3><p>Treatment of congenital thrombotic thrombocytopenic purpura (cTTP), a disease characterized by the congenital deficiency of ADAMTS13, remains a challenge as there are no specific treatments available yet, other than therapy based on the use of fresh frozen plasma (FFP). Since cTTP is caused by low levels of ADAMTS13 protein, commercially available coagulation factor concentrates have been considered as potential ADAMTS13 source in place of FFP. The study aimed to validate the therapeutic potential of a plasma-derived factor VIII (FVIII) product as a source of ADAMTS13.</p></div><div><h3>Methods</h3><p>The quantitation of ADAMTS13 activity levels in eight lots of a plasma-derived FVIII product, (Koāte®) was carried out with three different methodologies: a Fluorescence Resonance Energy Transfer (FRET) assay, a chemiluminescence assay, and a chromogenic ELISA. ADAMTS13 protein antigen levels were measured by the FRET technique as well. In addition, von Willebrand factor (VWF) activity (VWF ristocetin cofactor, VWF:RCo, and VWF collagen binding, VWF:CB) and antigen (VWF:Ag) were measured using chemiluminescence assays. Qualification protocols were applied to the methods used.</p></div><div><h3>Results</h3><p>The results showed high levels of ADAMTS13 in all eight Koāte® lots analyzed, with antigen and activity levels respectively of 10.72 IU/ml ± 3.94 and 5.62 IU/ml ± 1.39. Despite the significant content of ADAMTS13, VWF integrity seems not to be affected (0.81 ± 0.15 VWF:RCo/VWF:Ag and 0.75 ± 0.15 VWF:CB/VWF:Ag ratios).</p></div><div><h3>Conclusions</h3><p>These findings suggest that Koāte® could be a potential candidate for the treatment of cTTP, warranting evaluation in a clinical trial.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100120"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000244/pdfft?md5=49d22146b740dfdea8475cc368e91e07&pid=1-s2.0-S2666572722000244-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41538252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rate and risk factors for thromboembolism and major bleeding in adults with congenital heart disease taking vitamin K antagonist therapy","authors":"Daniel Samarai ,&nbsp;Sandra Lindstedt ,&nbsp;Nazim Isma ,&nbsp;Joanna Hlebowicz","doi":"10.1016/j.tru.2022.100122","DOIUrl":"10.1016/j.tru.2022.100122","url":null,"abstract":"<div><h3>Background</h3><p>The risk of adults with a congenital heart defect (ACHD) developing heart failure, stroke, arrhythmias, and the need for valve replacement is increased compared to healthy peers. Evidence for the use of novel oral anticoagulants (NOAC) in this patient group is still lacking and vitamin K antagonists (VKA) are the primary choice for patients with a mechanical valve. The present aim was to determine the rate of thromboembolic and major bleeding events in ACHD patients on VKA therapy.</p></div><div><h3>Methods</h3><p>This was a retrospective study on ACHD patients on VKA treatment registered in the National Quality Registry for Congenital Heart Disease, SWEDCON, and Atrial fibrillation and Anticoagulation, AuriculA, from Southern Sweden.</p></div><div><h3>Results</h3><p>213 patients were included with a mean age of 50 years (±18) years and a mean follow-up of 6.6 years (±3.3 years), 16% had complex defects and 41% had valvular VKA therapy indication. In total, 34 complications were registered, of which 14 were thromboembolic events and 20 were major bleeding events. The rate of thromboembolism and major bleeding events was 1.0 (95% CI: 0.6–1.6) and 1.4 (95% CI: 0.9–2.2) per 100 patient-years, respectively. Forty-three patients died during the study period. The mortality rate was 3.1 per 100 patient-years (95% CI: 2.2–4.1).</p></div><div><h3>Conclusion</h3><p>We found a low rate of thromboembolic events and major bleeding events for low-moderate risk ACHD patients with good quality of VKA anticoagulation. The target of TTR&gt;65% for ACHD patients is recommended.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100122"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000268/pdfft?md5=ab964f58c1ef523511f12c7b455dd658&pid=1-s2.0-S2666572722000268-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47868518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features, coagulation and inflammatory biomarkers associated with poor in-hospital outcomes in a Honduran population with RT-PCR confirmed COVID-19","authors":"David Aguilar-Andino ,&nbsp;Andrea N. Umaña ,&nbsp;César Alas-Pineda ,&nbsp;Freddy Medina Santos ,&nbsp;Alejandro Cárcamo Gómez ,&nbsp;Marco Molina Soto ,&nbsp;Ana Liliam Osorio","doi":"10.1016/j.tru.2022.100124","DOIUrl":"10.1016/j.tru.2022.100124","url":null,"abstract":"<div><h3>Background</h3><p>SARS-COV-2, in most cases, only generates a mild acute respiratory disease. However, patients with severe disease show an exaggerated response of the immune system, creating a pro-inflammatory state, which could cause abnormalities in the coagulation system that increases mortality. Latin American countries, specially those with limited resources, have few studies about clinical features, coagulation and inflammatory biomarkers that could be useful at admission to assess poor outcomes.</p></div><div><h3>Objective</h3><p>The objective of this study is to describe the clinical features, coagulation, and inflammatory biomarkers, and identify risk factors at admission that are associated poor outcomes in Honduran population.</p></div><div><h3>Methods</h3><p>A cohort study was conducted. 210 patients were included, which 105 died during hospitalization due to COVID-19 and 105 were discharged alive, between September 2020 and January 2021. Clinical and laboratorial data was retrospectively collected.</p></div><div><h3>Results</h3><p>57,6% of the population were male. The median age was 58 years. The median time between symptom onset and hospital admission was 6 days. D-dimer median was higher in the dead group compared with the alive group. Poor prognosis factors in the Cox multivariable model were male gender, age, symptom's duration, obesity and an elevated d dimer at admission.</p></div><div><h3>Conclusion</h3><p>In low-middle income countries, the assessment of these clinical and laboratory tools, especially in those with risk factors for prothrombotic states, could help clinicians to correctly stratify disease prognosis, establish a baseline to evaluate further evolution, and also predict outcomes, thus improving patient management.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100124"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000281/pdfft?md5=9150f9dcfa9bf43ea011462851bac35d&pid=1-s2.0-S2666572722000281-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47007013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective real-world meta-analysis of high-risk major bleeding as a primary safety outcome in cancer patients receiving therapeutic anticoagulation","authors":"Ritika Halder ,&nbsp;Eric Brucks ,&nbsp;Ce Cheng ,&nbsp;Kathylynn Saboda ,&nbsp;Hani M. Babiker ,&nbsp;Ali Mcbride ,&nbsp;Alejandro Recio-Boiles","doi":"10.1016/j.tru.2022.100121","DOIUrl":"10.1016/j.tru.2022.100121","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"9 ","pages":"Article 100121"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572722000256/pdfft?md5=90aef91be499c69d2c6f17b6df9fd052&pid=1-s2.0-S2666572722000256-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41720442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}